Capsaicin 8% patch has demonstrated efficacy and safety in improving pain, allodynia, and hyperalgesia associated with a wide range of localized peripheral neuropathy types.
Patients with osteoarthritis and knee pain who experience an early reduction in pain intensity when treated with duloxetine may experience long-term improvements in pain and quality of life from continued duloxetine intervention.
Medicinal cannabis may not effectively reduce opioid use or pain interference in individuals with chronic noncancer pain.
Most opioid overdose patients were male and lived in the Southern United States (39.3%).
Patients who received pregabalin and celecoxib had significantly lower pain scores and fewer patient-controlled analgesia button pushes than those who did not.
The growing body of research on marijuana and its effectiveness for pain management can be attributed to its recent legalization across multiple states in the United States.
Preemptive tapentadol may safely and effectively reduce postoperative pain in patients undergoing total knee arthroplasty.
Tramadol, although seldom prescribed in children, was found to be prescribed for almost half of children with contraindications for its use.
Duloxetine may not be effective in treating juvenile primary fibromyalgia syndrome.
Sufentanil sublingual tablets may be effective for the short-term postoperative or emergency department management of moderate to severe pain in patients from across the body mass index spectrum.
The acute treatment of migraine with lasmiditan may be safe and associated with short-term freedom from headache pain and reductions in bothersome headache symptoms.
Fast-dissolving oral piroxicam may represent an effective alternative to sublingual fentanyl for treating incidental breakthrough pain attacks caused by bone metastasis.
Parecoxib may be effective for postoperative pain following oral surgery and may be associated with fewer side effects than ketorolac.
Duloxetine may effectively prevent episodic migraine.
Chronic neuropathic pain has a large impact on quality of life and often causes or increases depressive symptoms for both men and women.
Mirogabalin may be efficacious and well tolerated in Asian individuals with postherpetic neuralgia or diabetic peripheral neuropathic pain.
Depression may partially mediate the association between post-traumatic stress disorder and opioid misuse.
Anticonvulsants may not effectively reduce pain or disability in patients with low back pain or lumbar radicular pain.
Ketamine may be superior to clonidine as an adjunct to epidural steroid injection of triamcinolone for patients with chronic low back pain.
In studies reporting on pharmacologic treatments for postherpetic neuralgia, few report the incidence of adverse events (AEs) or withdrawal rates due to AEs.
Adding methylcobalamin to pregabalin therapy has no advantage for patients with postherpetic neuralgia.
In patients with neuropathic pain conditions, low-dose lidocaine infusion therapy was found to be an effective treatment for short-term pain relief.
Allopurinol did not provide pain relief for patients with fibromyalgia pain over the course of 30 days.
Hyaluronic acid therapy may be more effective when supplemented with intra-articular platelet-rich plasma injections vs alone in treating primary knee osteoarthritis.
Clinical Pain Advisor will bring you live coverage of the 17th World Congress on Pain, held September 12 to 16, 2018, in Boston, Massachusetts.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds